Galgo: a bi-objective evolutionary meta-heuristic identifies robust transcriptomic classifiers associated with patient outcome across multiple cancer types
暂无分享,去创建一个
M E Guerrero-Gimenez | J M Fernandez-Muñoz | B J Lang | K M Holton | D R Ciocca | C A Catania | F C M Zoppino | K. Holton | B. Lang | D. Ciocca | Martin E. Guerrero-Gimenez | J. Fernandez-Muñoz | C. A. Catania | F. C. M. Zoppino | M. E. Guerrero-Gimenez | Benjamin J. Lang | F. C. Zoppino | J. M. Fernandez-Muñoz | Daniel R. Ciocca
[1] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[2] P. Rousseeuw. Silhouettes: a graphical aid to the interpretation and validation of cluster analysis , 1987 .
[3] John Quackenbush,et al. A three-gene model to robustly identify breast cancer molecular subtypes. , 2012, Journal of the National Cancer Institute.
[4] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[5] Aedín C. Culhane,et al. survcomp: an R/Bioconductor package for performance assessment and comparison of survival models , 2011, Bioinform..
[6] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[7] Benjamin Haibe-Kains,et al. Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer , 2012, PloS one.
[8] Peter J. Woolf,et al. GAGE: generally applicable gene set enrichment for pathway analysis , 2009, BMC Bioinformatics.
[9] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[10] K. Cibulskis,et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.
[11] Ian Krop,et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Yishai Shimoni,et al. Association between expression of random gene sets and survival is evident in multiple cancer types and may be explained by sub-classification , 2018, PLoS Comput. Biol..
[13] H. Johnsen,et al. Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers , 2011, PloS one.
[14] Matthew D. Wilkerson,et al. Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation , 2012, PloS one.
[15] P. Royston,et al. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt , 2011, Statistics in medicine.
[16] Benjamin J. Raphael,et al. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.
[17] M. Kris,et al. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Andreas Makris,et al. Clinical utility of gene-expression signatures in early stage breast cancer , 2017, Nature Reviews Clinical Oncology.
[19] Daniel B. Mark,et al. TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .
[20] Tom Ronan,et al. Avoiding common pitfalls when clustering biological data , 2016, Science Signaling.
[21] R. Greil,et al. A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors , 2011, Clinical Cancer Research.
[22] John H. Holland,et al. Adaptation in Natural and Artificial Systems: An Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence , 1992 .
[23] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Seon-Young Kim,et al. Gene-set approach for expression pattern analysis , 2008, Briefings Bioinform..
[25] Thomas Jansen,et al. Analysis of an Asymmetric Mutation Operator , 2010, Evolutionary Computation.
[26] M. Hallett,et al. Absolute assignment of breast cancer intrinsic molecular subtype. , 2015, Journal of the National Cancer Institute.
[27] Adam A. Margolin,et al. Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer , 2013, Science Translational Medicine.
[28] Jeanette J McCarthy,et al. Genomic Medicine: A Decade of Successes, Challenges, and Opportunities , 2013, Science Translational Medicine.
[29] F. Collins,et al. A new initiative on precision medicine. , 2015, The New England journal of medicine.
[30] Simen Myhre,et al. The importance of gene-centring microarray data. , 2010, The Lancet. Oncology.
[31] Gregory M. Chen,et al. Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma , 2018, Clinical Cancer Research.
[32] Richard M. Simon,et al. Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data , 2011, Briefings Bioinform..
[33] Nofisat Ismaila,et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2016, Journal of oncology practice.
[34] Andrew E. Jaffe,et al. Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .
[35] Kalyanmoy Deb,et al. A fast and elitist multiobjective genetic algorithm: NSGA-II , 2002, IEEE Trans. Evol. Comput..
[36] E. Goode,et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. , 2014, Journal of the National Cancer Institute.
[37] Joel S. Parker,et al. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer , 2016, Bioinform..
[38] R. Tibshirani,et al. Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.
[39] Prasad Patil,et al. Test set bias affects reproducibility of gene signatures , 2015, Bioinform..
[40] Jeffrey S. Morris,et al. The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.
[41] David Venet,et al. Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome , 2011, PLoS Comput. Biol..
[42] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[43] L. Murphy,et al. Genes and functions from breast cancer signatures , 2018, BMC Cancer.